

COMPANY PROFILE

Kedrion Biopharma is a biopharmaceutical company dedicated to collecting and fractionating blood plasma to produce and distribute plasma-derived therapies worldwide. These treatments help manage and prevent rare, ultra-rare, and debilitating conditions, including Coagulation and Neurological Disorders, Immunodeficiencies, and Rh sensitization.

At Kedrion, science meets humanity, ensuring that innovation and care go hand in hand. Every detail, every patient, and every interaction matter. Partnerships with the medical-scientific community, institutions, patient advocacy groups, and research bodies foster sustainable innovation and improve patient care. These “rare connections” not only transform lives but also drive business forward.

With over a century of experience, the company’s legacy spans multiple centers of excellence. Expertise dates back more than 100 years in Hungary (Gödöllő, Budapest), over 70 years in the UK (Elstree, London), and extends across specialized facilities in Italy (Bolognana and Castelvechio Pascoli, Lucca; Sant’Antimo, Naples), North America (Melville, New York, USA; Laval, Québec, Canada), and beyond. Each site serves as a boutique of excellence, contributing to the fractionation of 3,5 million liters of plasma annually. Customizing production processes and strategically locating operations ensure the efficient service of diverse markets and the ability to meet the needs of patients worldwide.

Since its foundation, Kedrion has experienced consistent growth, backed by strong performance indicators. Today, the company employs more than 5,400 people globally and operates a vast plasma collection network, with 67 centers under KEDPLASMA in the United States and 8 under UNICAPlasma in the Czech Republic. These centers supply fractionation facilities with essential plasma, supporting an extensive portfolio of 39 products distributed in over 100 countries. A significant presence in the United States, the industry’s most relevant market, accounts for more than 60% of total revenue.

In Italy, where the parent company was founded in 2001, Kedrion plays a crucial role in the national plasma-derived therapies sector. As a key partner of the Italian Health System, the company supports efforts to achieve self-sufficiency in plasma-derived product supply, reinforcing its commitment to public health.

More than just a producer of plasma-derived therapies, Kedrion is a trusted partner to the medical community. Through collaboration, innovation, and an unwavering dedication to care, the goal is to create a world where scientific advancement and human compassion go together. Every connection - whether with donors, patients, employees, or partners - has a lasting impact. We call these “rare connections”.

www.kedrion.com